GlassScriptPhysician profile
Marcela Eugenia Ramirez
NPI 1730572306
$5,640.74
in general payments reported to CMS, 2019-2025
18 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $158 · 2023: $2,336 · 2024: $1,479 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Education: $93.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Education | $93.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,549.11 | 2021-2025 | |
| Revance Therapeutics, INC. | $1,123.65 | 2024-2025 | Daxxify, Daxi |
| Merz North America, INC. | $528.55 | 2022-2025 | Xeomin |
| Galderma Laboratories, L.P. | $462.93 | 2021-2025 | |
| Ucb, INC. | $210.75 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $148.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $129.43 | 2024-2025 | |
| Janssen Biotech, INC. | $100.93 | 2021-2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Leo Pharma INC. | $78.40 | 2021-2025 | Adbry |
| Lilly USA, LLC | $49.36 | 2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $45.92 | 2023 | |
| Allergan, INC. | $43.23 | 2021 | |
| Dermavant Sciences, INC. | $23.11 | 2024 | Vtama |
| Incyte Corporation | $23.01 | 2025 | Opzelura |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $20.76 | 2021 | |
| Fidia Pharma USA INC. | $16.96 | 2025 | |
| Organon LLC | $1.23 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.